Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience

BACKGROUND: Despite the clinical benefit of immune checkpoint inhibitors (ICIs), patients with a viral hepatitis have been excluded from clinical trials because of safety concerns. The purpose of this study was to determine the incidence rate of adverse events (AEs) in patients with viral hepatitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Nardo, Mirella, Yilmaz, Bulent, Nelson, Blessie Elizabeth, Torres, Harrys A, Wang, Lan Sun, Granwehr, Bruno Palma, Song, Juhee, Dalla Pria, Hanna R F, Trinh, Van A, Glitza Oliva, Isabella C, Patel, Sapna P, Tannir, Nizar M, Kaseb, Ahmed Omar, Altan, Mehmet, Lee, Sunyoung S, Miller, Ethan, Zhang, Hao, Stephen, Bettzy A, Naing, Aung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Immuno-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400154/
https://www.ncbi.nlm.nih.gov/pubmed/36952233
http://dx.doi.org/10.1093/oncolo/oyad039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400154/
https://www.ncbi.nlm.nih.gov/pubmed/36952233
http://dx.doi.org/10.1093/oncolo/oyad039

Ejemplares similares